Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Sweden
  4. Nasdaq Stockholm
  5. Biovica International AB (publ)
  6. News
  7. Summary
    BIOVIC B   SE0008613731

BIOVICA INTERNATIONAL AB (PUBL)

(BIOVIC B)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Biovica announces the start of the TK IMPACT trial at Washington University of St Louis

11/24/2021 | 02:01am EST

Biovica, active in cancer diagnostics, today announces initiation of the TK IMPACT study, an investigator initiated prospective clinical trial at Washington University of St Louis to evaluate the clinical utility of Biovica’s blood-based biomarker assay DiviTum®TKa on monitoring practices in the care of metastatic breast cancer patients.

The study hypothesis is that incorporation of data from DiviTum®TKa measurements into the treatment monitoring of patients receiving standard first line treatment with CDK 4/6 inhibitors plus endocrine therapies, will be associated with the physicians’ decision to change usage and/or timing of other routine monitoring tests such as CT scans and nuclear medicine exams. The study will examine care over time of 55 patients that will be tested regularly with DiviTum®TKa.

“We are proud to support the TK IMPACT study which is a key step forward in the development of DiviTum®TKa as it examines the clinical utility of the test on actual care of metastatic breast cancer patients. Our vision is to change the standard of care in monitoring to easy, fast and safe blood-based TKa testing”, said Biovica’s CEO Anders Rylander.

“An increasing number of our patients with metastatic breast cancer go for many months, even years, without their disease progressing. Nonetheless, as today’s standard practice, we often bring them in for repeat imaging exams every three months. This is a burden on the patients. We believe that a convenient blood-based test will enable us to make changes that improve our patients’ lives. We are excited to test our ability to make changes in this study” said Dr Nusayba Bagegni, the principal investigator of the study.
 
Earlier studies have demonstrated that patients with low TKa levels have extended times to disease progression, which enables the possibility to modify and reduce usage of other monitoring exams such as imaging. These other exams represent a burden both on patients and on healthcare costs.

To provide patients, their families, healthcare professionals, and the public with the information about the clinical trial, the TK IMPACT study is listed on the ClinicalTrials.gov website: (https://clinicaltrials.gov/ct2/show/NCT04968964?term=Bagegni&draw=2&rank=1)

© Modular Finance, source Nordic Press Releases

All news about BIOVICA INTERNATIONAL AB (PUBL)
2021Biovica International
AQ
2021Q2 Interim report - Promising results published at ESMO
AQ
2021Biovica International AB Reports Earnings Results for the Second Quarter and Six Months..
CI
2021Biovica International AB Provides Earnings Guidance for the Full Year 2021
CI
2021Biovica announces the start of the TK IMPACT trial at Washington University of St Louis
AQ
2021Biovica announces the start of the TK IMPACT trial at Washington University of St Louis
CI
2021Biovica International
AQ
2021Biovica's DiviTum«TKa in three studies at SABCS 2021
AQ
2021Biovica International AB Announces Results from Three Different Studies Using Divitum?T..
CI
2021Biovica International
AQ
More news
Financials
Sales 2022 39,0 M 4,24 M 4,24 M
Net income 2022 -28,0 M -3,05 M -3,05 M
Net cash 2022 110 M 12,0 M 12,0 M
P/E ratio 2022 -37,9x
Yield 2022 -
Capitalization 1 068 M 116 M 116 M
EV / Sales 2022 24,6x
EV / Sales 2023 5,13x
Nbr of Employees 24
Free-Float -
Chart BIOVICA INTERNATIONAL AB (PUBL)
Duration : Period :
Biovica International AB (publ) Technical Analysis Chart | BIOVIC B | SE0008613731 | MarketScreener
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 1
Last Close Price 37,50 SEK
Average target price 103,00 SEK
Spread / Average Target 175%
EPS Revisions
Managers and Directors
Anders Rylander Chief Executive Officer & Director
Cecilia Driving CFO, Head-Human Resource, IR & EVP
Lars Erik Holmqvist Chairman
Mattias Bergqvist Director-Clinical Development
Otti Bengtsson Gref Director-Research & Development
Sector and Competitors
1st jan.Capi. (M$)
BIOVICA INTERNATIONAL AB (PUBL)-9.42%116
EXACT SCIENCES CORPORATION-4.88%12 757
GUARDANT HEALTH, INC.-29.91%7 126
BGI GENOMICS CO., LTD.1.37%5 755
SEEGENE, INC.-1.31%2 606
INVITAE CORPORATION-29.21%2 447